These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1415368)

  • 1. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.
    Veys N; Dhondt A; Lameire N
    Clin Nephrol; 1998 Jan; 49(1):41-4. PubMed ID: 9491285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.
    Granolleras C; Leskopf W; Shaldon S; Fourcade J
    Clin Nephrol; 1991 Dec; 36(6):294-8. PubMed ID: 1769141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.
    Berthoux F; Ryckelynck JP; Rouanet S; Gelu-Mantoulet S; Montestruc F; Mouchel P; Choukroun G;
    Clin Nephrol; 2008 Jul; 70(1):33-40. PubMed ID: 18793546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 9. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study with recombinant human erythropoietin.
    Tanaka H; Kan E; Takegaki Y; Inariba H; Yoshimoto M; Ohno Y; Maekawa M; Tatsumi N; Kishimoto T
    Artif Organs; 1993 Apr; 17(4):213-8. PubMed ID: 8498899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
    Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
    Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients.
    Schmitt CP; Nau B; Brummer C; Rosenkranz J; Schaefer F
    Nephrol Dial Transplant; 2006 Dec; 21(12):3520-4. PubMed ID: 16935904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure.
    Tilkian EE; Tzekov VD; Pandeva SM; Kumchev EP; Nikolov DG; Dimitrakov JD; Dimitrakov DD
    Folia Med (Plovdiv); 2000; 42(3):11-5. PubMed ID: 11347329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.
    Eisele G; Bailie GR; Clement C; Wong E
    Perit Dial Int; 1992; 12(1):34-6. PubMed ID: 1543777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha].
    Molina M; García Hernández MA; Navarro MJ; De Gracia MC; Ortuño T
    Nefrologia; 2004; 24(6):564-71. PubMed ID: 15683029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.